Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8744825 | Clinical Microbiology and Infection | 2018 | 33 Pages |
Abstract
MDRO account for nearly one-third of BSI in cirrhotic patients, often resulting in delayed or inadequate empirical antimicrobial therapy and increased mortality rates. Our data suggest that improved prevention and treatment strategies for MDRO are urgently needed in the liver cirrhosis patients.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
M. Bartoletti, M. Giannella, R. Lewis, P. Caraceni, S. Tedeschi, M. Paul, C. Schramm, T. Bruns, M. Merli, N. Cobos-Trigueros, E. Seminari, P. Retamar, P. Muñoz, M. Tumbarello, P. Burra, M. Torrani Cerenzia, B. Barsic, E. Calbo, S. Grieco,